Rapid and sustained control of itch and reduction in Th2 bias by dupilumab in a patient with Sézary syndrome

Abstract

In this Sézary patient, inhibition of IL-4 and IL-13 signalling was associated with striking clinical benefit in terms of quality of life, pruritus and use of topical corticosteroids. While safety remains an important concern, our data support the future exploration of Th2 modulation for supportive care in Sézary Syndrome.